RESEARCH ARTICLE

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)

June Young Chun1*†, Hwichang Jeong2† and Yongdai Kim2*

Abstract

Background: The Omicron variant (B.1.1.529) is estimated to be more transmissible than previous strains of SARS-CoV-2, especially among children, potentially resulting in croup which is a characteristic disease in children. Current coronavirus disease 2019 (COVID-19) cases among children might be higher because (i) school-aged children have higher contact rates and (ii) the COVID-19 vaccination strategy prioritizes the elderly in most countries. However, there have been no reports confirming the age-varying susceptibility to the Omicron variant to date.

Methods: We developed an age-structured compartmental model, combining age-specific contact matrix in South Korea and observed distribution of periods between each stage of infection in the national epidemiological investigation. A Bayesian inference method was used to estimate the age-specific force of infection and, accordingly, age-specific susceptibility, given epidemic data during the third (pre-Delta), fourth (Delta driven), and fifth (Omicron driven) waves in South Korea. As vaccine uptake increased, individuals who were vaccinated were excluded from the susceptible population in accordance with vaccine effectiveness against the Delta and Omicron variants, respectively.

Results: A significant difference between the age-specific susceptibility to the Omicron and that to the pre-Omicron variants was found in the younger age group. The rise in susceptibility to the Omicron/pre-Delta variant was highest in the 10–15 years age group (5.28 times [95% CI, 4.94–5.60]), and the rise in susceptibility to the Omicron/Delta variant was highest in the 15–19 years age group (3.21 times [95% CI, 3.12–3.31]), whereas in those aged 50 years or more, the susceptibility to the Omicron/pre-Omicron remained stable at approximately twofold.

Conclusions: Even after adjusting for contact pattern, vaccination status, and waning of vaccine effectiveness, the Omicron variant of SARS-CoV-2 tends to propagate more easily among children than the pre-Omicron strains.

Keywords: SARS-CoV-2, COVID-19, B.1.1.529 SARS-CoV-2 variant, Mathematical model, Bayesian analysis, Child, Adolescent, Susceptibility

Background

As the Omicron variant (B.1.1.529) of SARS-CoV-2 drives a new surge in coronavirus disease 2019 (COVID-19) cases globally, increasing proportion of pediatric cases is noteworthy [1]. In the United States (US), where the Omicron variant had been predominant since December 2021, the seroprevalence of infection-induced SARS-CoV-2 antibodies among children aged 0–11 years increased from 44.2 to 75.2% during December 2021 to
February 2022, recording the highest increase among all age groups (overall US seroprevalence increased from 33.5 to 57.7%) [2]. In England, pediatric admissions with COVID-19 infections began to rise since December 26, 2021, from an average of 40 admissions per day to 120 per day, a 3-fold rise in 2 weeks [3].

The rise in pediatric cases might be attributed to the elderly-prioritized vaccination strategy against COVID-19 and relatively higher contact rates among school-aged children than adults. As of May 31, 2022, the World Health Organization (WHO) authorized COVID-19 vaccines for individuals aged 18 years and older, and only one vaccine could be used for individuals from 5 years of age, which let children more vulnerable to COVID-19 [4]. Otherwise, children might genuinely be more susceptible to contracting the Omicron infections than adults. Identifying the age-specific susceptibility to SARS-CoV-2 is of much interest for effective public health strategies and vaccination policy. However, it is often not easy to clarify the age-specific susceptibility to an infection due to the lack of sufficient data.

In South Korea, the biggest 5th wave has been driven by the Omicron variant since January 2022, following the 4th wave by the Delta variant and the 3rd wave by the original SARS-CoV-2 virus (Fig. 1A). Here, we attempted to identify the age-specific susceptibility to the Omicron variant compared to the Delta and the pre-Delta strains, using the epidemiologic data of those three waves along with vaccine coverage data in South Korea. The force of infection \( \lambda_i \) experienced by age group \( i \) was used to estimate the age-specific susceptibility in this study [5]. Given that South Korea has the National Infectious Disease Surveillance System (NIDSS) which mandates the web-based reporting of every COVID-19 case and the National Immunization Registry, it could be a suitable country to elucidate this topic [6, 7]. Considering the concordance between the laboratory-confirmed COVID-19 incidence and the national seroprevalence of SARS-CoV-2-specific anti-nucleocapsid (anti-N) antibodies (Fig. 1B), the ascertainment ratio in South Korea may not be far from reality [8].

**Methods**

We adapted a previously described model which estimated the age-varying susceptibility to the Delta variant [9] and updated the model with recent vaccine coverage data and waning of vaccine effectiveness against the Omicron infection.

**Data**

Age-stratified daily COVID-19 incidence and vaccine uptake rates have been reported in public by the Ministry of Health and Welfare of South Korea through NIDSS and National Immunization Registry [7, 8, 10]. More refined vaccination data of doses and manufacturers were provided by Korea Disease Control and Prevention Agency (KDCA) and National Health Insurance Service (NHIS). Age-structured population data was obtained from the Statistics Korea [11].

**Model construction**

Following our previous study, we built an age-structured compartmental model stratified into 5-year age bands [9]. Compartments in the model were stratified by infection states (i.e., susceptible [S], exposed [E], infectious and pre-symptomatic [I\text{presym}], infectious and symptomatic [I\text{sym}], infectious and asymptomatic [I\text{asym}], or quarantined [Q]), age band, and the transition time to the next infection state (Additional file 1: eMethods). In South Korea, individuals diagnosed with COVID-19 are isolated immediately; thus, the confirmation date could be regarded as the date on which quarantine started.

The strength of this model is that we know the diagnostic delay distribution (symptom onset to \( Q \)), transmission onset distribution relative to the symptom onset (\( I \) given symptom onset), and latent period distribution (\( E \) to \( I \)), based on the robust contact tracing study in South Korea (Table 1) [12]. For those who had never developed any symptoms (I\text{asym}), we assumed that their latent period distribution was the same as that of individuals who developed symptoms (I\text{presym} \rightarrow I\text{sym}) and that their infectious period distribution was the same as the total infectiousness period distribution of symptomatic individuals as suggested [13]. With this backward inference method, the remaining unknown distribution was the transition time from \( S \) to \( E \), which depends on the force of infection. To estimate the parameters in the force of infection, we used a Bayesian inference method with a carefully designed Markov chain Monte Carlo (MCMC) algorithm. In this MCMC algorithm, we inferred the exposure times conditional on that the force of infection for each age group \( i \) was known and then inferred the force of infection given that the exposure times were available. We repeated these two steps several times until the Markov chain converged.

According to Vynnycky and White [22], the force of infection \( \lambda_i \) is written as follows:

\[
\lambda_i = \sum_j \beta_{ij}I_j
\]

Here, \( \beta_{ij} \) is the rate at which susceptible individuals in the age group \( i \) and infectious individuals in the age group \( j \) come into effective contact per unit time, and \( I_j \) is the number of infectious individuals in the age group \( j \). We further divide \( \beta_{ij} \) into:
Fig. 1 Characteristics of the SARS-CoV-2 outbreak in South Korea: A epidemic curve and national interventions, B national seroprevalence data*, and C domestic composition of variant strains during the study period. *The seroprevalence of SARS-CoV-2-specific anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies have been studied in samples from the Korea National Health and Nutrition Examination Survey which included participants aged 10 years or more. The seroprevalence study was performed in samples from blood donors (aged 20 to 59 years) in December 2021, only. The number denotes the sample size of each study.
| Table 1  | Model parameters                                                                 | Value                                                                                           | Ref |
|----------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----|
| Incubation period | *Gamma* ($\mu=4.544, k=1/0.709$)                                               |                                                  | [12]|
| Transmission onset relative to the symptom onset | $-4 + \Gamma (\mu=5.266, k=1/0.8709)$ |                                                  | [12]|
| Latent period       | Incubation period + transmission onset relative to symptom onset                |                                                  | [12]|
| Delays from symptom onset to diagnosis   | Empirical distribution from the raw data                                        |                                                  | [12]|
| Infectious period for asymptomatic cases   | *Gamma* ($\mu=4, k=4/5$)                                                        |                                                  | [13]|
| Proportion of asymptomatic cases           | 52%, 50%, 45%, and 12% among individuals aged 0–4, 5–11, 12–17, and ≥18 years, respectively; or 50% in all age groups during the Omicron wave for sensitivity analysis |                                                  | [14]|
| Relative infectiousness of asymptomatic cases | 50% (25–75%)                                                                  |                                                  | [13, 15, 16]|
| Age groups (years)                          | [0–5], [5–10], [10–15], [15–20], [20–25], [25–30], [30–40], [40–45], [45–50], [50–55], [55–60], [60–65], [65–70], [70–75], [≥75] |                                                  |     |
| Vaccine effectiveness against the Delta variant infection | BNT162b2 one dose ≥21 days: 57% (95% CI 50–63%)                                  |                                                  | [17–20]|
|                                                  | BNT162b2 two doses >14 days: 80% (95% CI 77–83%)                                 |                                                  |     |
|                                                  | ChAdOx1 one dose ≥21 days: 46% (95% CI 35–55%)                                   |                                                  |     |
|                                                  | ChAdOx1 two doses >14 days: 67% (95% CI 62–71%)                                   |                                                  |     |
|                                                  | mRNA-1273 one dose ≥21 days: 75% (95% CI 64–83%)                                 |                                                  |     |
|                                                  | mRNA-1273 two doses >14 days: 85% (95% CI 84–89%)                                |                                                  |     |
|                                                  | Ad26.COV2.S >14 days: 69% (95% CI 67–71%)                                       |                                                  |     |
| Vaccine effectiveness against the Omicron variant infection | BNT162b2 one dose ≥18 days: 42.8% (95% CI 40.3–45.1%)                            |                                                  | [21]|
|                                                  | BNT162b2 one dose >42 days: 31.5% (95% CI 29.9–33.1%)                            |                                                  |     |
|                                                  | BNT162b2 two doses <14 days: same value with one dose                            |                                                  |     |
|                                                  | BNT162b2 two doses >21 days: 65.5% (95% CI 63.9–67.0%)                           |                                                  |     |
|                                                  | BNT162b2 two doses >49 days: 48.7% (95% CI 47.1–50.2%)                           |                                                  |     |
|                                                  | BNT162b2 two doses >84 days: 30.1% (95% CI 28.7–31.5%)                           |                                                  |     |
|                                                  | BNT162b2 two doses >19 days: 15.4% (95% CI 14.2–16.6%)                           |                                                  |     |
|                                                  | BNT162b2 two doses >154 days: 11.5% (95% CI 10.1–12.9%)                          |                                                  |     |
|                                                  | BNT162b2 two doses >189 days: 8.8% (95% CI 7.0–10.5%)                            |                                                  |     |
|                                                  | Interpolate linearly in between                                                 |                                                  |     |
|                                                  | ChAdOx1 one dose ≥18 days: 17.7% (95% CI 14.3–21.0%)                            |                                                  |     |
|                                                  | ChAdOx1 one dose >42 days: 16.7% (95% CI 12.3–20.0%)                            |                                                  |     |
|                                                  | ChAdOx1 two doses <14 days: same value with one dose                             |                                                  |     |
|                                                  | ChAdOx1 two doses >21 days: 48.9% (95% CI 39.2–57.1%)                           |                                                  |     |
|                                                  | ChAdOx1 two doses >49 days: 33.7% (95% CI 25.0–41.5%)                           |                                                  |     |
|                                                  | ChAdOx1 two doses >84 days: 28.6% (95% CI 20.9–35.6%)                           |                                                  |     |
|                                                  | ChAdOx1 two doses >119 days: 17.8% (95% CI 13.4–21.9%)                          |                                                  |     |
|                                                  | ChAdOx1 two doses >154 days: 4.0% (95% CI 1.9–6.1%)                             |                                                  |     |
|                                                  | ChAdOx1 two doses >189 days: 0%                                                 |                                                  |     |
|                                                  | Interpolate linearly in between                                                 |                                                  |     |
|                                                  | mRNA-1273 one dose ≥18 days: 47.9% (95% CI 43.1–52.3%)                          |                                                  |     |
|                                                  | mRNA-1273 one dose >42 days: 31.9% (95% CI 27.3–36.1%)                          |                                                  |     |
|                                                  | mRNA-1273 two doses <14 days: same value with one dose                          |                                                  |     |
Here, $q_i$ is the probability that a contact between a susceptible individual in age group $i$ and an infectious person leads to infection, $\phi_{ij}$ is the number of contacts an individual in age group $j$ makes with those in age group $i$ per unit time, and $n_i$ is the number of individuals in age group $i$. Since we know the contact matrix for South Korea and the age-stratified incidence of COVID-19 at discrete time $t$, we could infer the $\lambda_i$ (accordingly $q_i$) of age group $i$ \cite{23}. To capture the changes of contact patterns as a result of social distancing measures, we considered school closure policies and reduced contact rates both at work and other places using Google mobility data (Fig. 1A, Additional file 1: Table S1 to S2) \cite{24, 25}. Detailed Bayesian inference methods are available in Additional file 1: eMethods. All analyses were conducted using the Python statistical software version 3.6.13.

**Study period**

The age-specific susceptibility ($q_i$) during the 5th wave (Omicron driven, from January 1 to January 31, 2022) were compared with those during the 4th (Delta driven, from June 27 to August 21, 2021) and 3rd (pre-Delta, from October 15 to December 22, 2020) waves in South Korea. Since we know the domestic composition of variants during the study period (Fig. 1C), we only take into account the Omicron infections during the 5th wave and the Delta infections during the 4th wave.

As vaccine uptake increased, individuals who were vaccinated have been excluded from the susceptible population in accordance with the vaccine effectiveness against the Delta and the Omicron variants. The waning of vaccine effectiveness was also considered \cite{21}. In detail, age-specific vaccine coverage data by vaccine doses and manufacturers have been reported weekly by the Ministry of Health and Welfare of South Korea (Additional file 1: Table S3) \cite{7}. We divided the weekly number of immunized individuals by 7 to get a daily number of immunized individuals for the corresponding week and removed them from the susceptible population 2 weeks after the vaccination, considering the time to achieve immunity against COVID-19.

**Sensitivity analysis**

There are uncertainties about these model parameters, including the age-specific contact patterns, the

| Value | Ref |
|-------|-----|
| mRNA-1273 two doses >21 days: 75.1% (95% CI 70.8–78.7%) | mRNA-1273 two doses >49 days: 52.8% (95% CI 48.2–57.1%) |
| mRNA-1273 two doses >84 days: 35.6% (95% CI 32.7–38.4%) | mRNA-1273 two doses >119 days: 25.3% (95% CI 23.2–27.4%) |
| mRNA-1273 two doses >154 days: 15.0% (95% CI 11.6–18.2%) | mRNA-1273 two doses >189 days: 14.9% (95% CI 3.9–24.7%) |
| Ad26.COV2.S<sup>a</sup> | Booster dose<sup>b</sup> >10 days: 67.3% (95% CI 65.9–68.6%) |
| Booster dose<sup>b</sup> >21 days: 66.9% (95% CI 65.6–68.1%) | Booster dose<sup>b</sup> >49 days: 55.0% (95% CI 54.2–55.8%) |
| Booster dose<sup>b</sup> >84 days: 45.7% (95% CI 44.7–46.7%) | Interpolate linearly in between |

<sup>a</sup> We regarded the vaccine effectiveness against the Omicron infection of Ad26.COV2.S was the same as that of ChAdOx1 due to unavailable reference data

<sup>b</sup> Whatever vaccine was used before (BNT162b2, ChAdOx1, mRNA-1273, or Ad26.COV2.S), we regarded the vaccine effectiveness of the booster dose as the same. In South Korea, BNT162b2 and mRNA-1273 have been used for booster shots approximately in a 2:1 ratio; thus, the weighted average of vaccine effectiveness values was used.

$$\beta_{ij} = q_i \frac{\phi_{ij}}{n_i}$$

$\beta_{ij}$ is the probability that a contact between a susceptible individual in age group $i$ and an infectious person leads to infection, $\phi_{ij}$ is the number of contacts an individual in age group $j$ makes with those in age group $i$ per unit time, and $n_i$ is the number of individuals in age group $i$. Since we know the contact matrix for South Korea and the age-stratified incidence of COVID-19 at discrete time $t$, we could infer the $\lambda_i$ (accordingly $q_i$) of age group $i$ \cite{23}. To capture the changes of contact patterns as a result of social distancing measures, we considered school closure policies and reduced contact rates both at work and other places using Google mobility data (Fig. 1A, Additional file 1: Table S1 to S2) \cite{24, 25}. Detailed Bayesian inference methods are available in Additional file 1: eMethods. All analyses were conducted using the Python statistical software version 3.6.13.
proportion of individuals who were infected and asymptomatic, and vaccine effectiveness. Therefore, we varied those values with sensitivity analyses. First, the number of contacts made in school was varied from 0.8-fold to 1.2-fold to the baseline, given that school-aged children have higher contact rates compared with other age groups and were likely to affect the result most. Second, considering the high asymptomatic infections with the Omicron variant, we increased the proportion of asymptomatic infections to 50% in all age groups [26]. At baseline, we adopted the prospective household cohort study reporting age-varying asymptomatic proportions (i.e., 52%, 50%, 45%, and 12% among individuals aged 0–4 years, 5–11 years, 12–17 years, and ≥18 years, respectively) [14]. For vaccine effectiveness, we adopted lower and upper bounds of the 95% confidence interval (CI) for sensitivity analyses as reported in another study [21].

Results

The age distribution of COVID-19 cases during the 3rd (pre-Delta), 4th (Delta), and 5th (Omicron) waves in South Korea is shown in Fig. 2A, B. The proportions of COVID-19 cases among those aged 19 years or less were 11.02%, 10.16%, and 11.02% during the 3rd, 4th, and 5th waves, respectively. Meanwhile, the proportions of cases among those aged 60 years or more were 28.47%, 10.16%, and 11.02% during the 3rd, 4th, and 5th waves, respectively. Considering the age demographics (age skewed older in South Korea), the normalized proportions of cases by age structure among those aged 19 years or less were 28.47%, 10.16%, and 10.04% during the 3rd, 4th, and 5th waves, respectively. Considering the age demographics (age skewed older in South Korea), the normalized proportions of cases by age structure among those aged 19 years or less were 28.47%, 10.16%, and 10.04% during the 3rd, 4th, and 5th waves, respectively. Considering the age demographics (age skewed older in South Korea), the normalized proportions of cases by age structure among those aged 19 years or less were 28.47%, 10.16%, and 10.04% during the 3rd, 4th, and 5th waves, respectively.

The estimated age-specific susceptibility to COVID-19 is shown in Fig. 2C, D. Both the 3rd (pre-Delta) and 4th (Delta) waves showed a similar age-dependent increase, whereas the 5th (Omicron) wave showed an inverted bell curve with bimodal peaks. A significant difference between the susceptibility to the Omicron and that to the Delta and pre-Delta variants was found in the younger age group. The rise in susceptibility to the Omicron/pre-Delta variant was highest in the 10–15 years age group (5.28 times [95% CI, 4.94–5.60]), whereas in those aged 50 years or more, the susceptibility to the Omicron/pre-Delta remained stable at approximately twofold, scoring the lowest value of 1.12 (95% CI, 1.09–1.14) among those aged 75 years or more. The rise in susceptibility to the Omicron/Delta variant was highest in the 15–19 years age group (3.21 times [95% CI, 3.12–3.31]) and lowest in those aged 75 years or more (0.93 times [95% CI, 0.89–0.97]).

For validation, we simulated the model forward with the estimated susceptibility parameters during the training period and verified the estimated case numbers could reproduce the observed epidemiological patterns equally well. We also presented the convergence of the Markov chain Monte Carlo (MCMC) algorithm through the trace plots and autocorrelation function (ACF) of the parameters. Varying the contact patterns, proportion of asymptomatic cases, and vaccine effectiveness in sensitivity analyses, the rise in susceptibility to the Omicron/pre-Omicron was not changed, recording the higher values in the 0–19 years age groups than in other age groups (Additional file 1: Fig. S1 to S12).

Discussion

Even after adjusting for contact pattern, vaccination status, and waning of vaccine effectiveness, the age-specific susceptibility among age group 0–19 years was approximately 5 times higher during the 5th wave (Omicron driven) than that during the 3rd wave (pre-Delta) and 3 times higher than that during the 4th wave (Delta driven). Indeed, children are more susceptible to the Omicron variant compared with the previous strains of SARS-CoV-2. According to the US Centers for Disease Control and Prevention report, the hospitalization rates among individuals aged 12–17 years were 3.5 times as high during the peak week of the Omicron period than during the Delta period [27]. Previously mentioned pediatric admissions with COVID-19 infections in England also showed a 3-fold rise in 2 weeks from December 26, 2021 [3]. These findings are in line with our result, although the increased susceptibility to the infection is not necessarily correlated with the increased hospitalization rates.

Considering that the Omicron variant has shifted tropism to the upper respiratory tract from the lower respiratory tract, children whose upper airway is immature and relatively smaller than those in adults could be much more easily affected [28, 29]. Likewise, increasing cases of croup, an acute laryngotracheobronchitis characterized by barking cough, were noted in South Korea, during the Omicron surge [30]. What is more, the endocytic entry which Omicron prefers over the angiotensin-converting enzyme 2 (ACE2)-dependent pathway could also explain the higher number of pediatric cases since children have a lower number of ACE receptors [31, 32]. Taken together, our finding is in accordance with both epidemiological and biological observations.

There are several limitations in this study. First, the contact matrix in this study was not of our own empirical data, but instead mathematically estimated data.
Second, although we attempted to reflect the social distancing policy into our model, the implementation of nonpharmaceutical interventions (NPI), which could change the effective contact rates, was not fully considered in this study. However, the essential measures such as mask mandate, contact tracing, and mandatory quarantine for international arrival have been applied consistently throughout the study period (Additional file 1: Table S1). Moreover, the relative increase in susceptibility within the same age group would not change much, given the NPI use was likely to be consistent among the same age group [33]. Third, the exact proportion of asymptomatic infections by age groups remains unclear. To overcome this hurdle, we adopted the result from a prospective cohort study and further conducted a sensitivity analysis with variable ranges of asymptomatic proportions [14]. In addition, public health authorities in South Korea had conducted a mass screening test for those who had contact with confirmed COVID-19 cases until February 2022. For example, if there was one case in a school, whole classmates (occasionally whole students in the school) and their parents were screened for SARS-CoV-2 with either polymerase chain reaction (PCR) or rapid antigen test. Thus, we think it is unlikely to miss a significant number of cases in South Korea.

Conclusions

In conclusion, large-scale testing, prompt epidemiological survey, and vaccination status records in a national registry in South Korea allowed us to analyze the age-stratified susceptibility to SARS-CoV-2. Generally, the Omicron variant of SARS-CoV-2 was estimated to spread more easily among children than the Delta and pre-Delta strains. At the beginning of the SARS-CoV-2 pandemic, an increased number of cases and a greater risk of severe disease with increasing age were notable. We might now see the course of adaptation of novel SARS-CoV-2 to humans. This age affinity seems to be similar with influenza that we include both the youngest and the elderly as target groups for vaccination. Although it is not yet clear whether children could be key driver groups in SARS-CoV-2 transmission hereafter, additional efforts for vaccinating children might be considered to reduce the pandemic’s impact on the whole community.

Abbreviations

ACE2: Angiotensin-converting enzyme 2; ACF: Autocorrelation function; anti-N: Anti-nucleocapsid; CI: Confidence interval; COVID-19: Coronavirus disease 2019; E: Exposed; Iasym: Infectious and asymptomatic; Ipresym: Infectious and pre-symptomatic; Isym: Infectious and symptomatic; MCMC: Markov chain Monte Carlo; NIDSS: National Infectious Disease Surveillance System; NPI: Nonpharmaceutical interventions; Q: Quarantined; S: Susceptible; US: United States; WHO: World Health Organization.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02655-z.

Additional file 1: eMethods. Bayesian inference method to estimate the age-varying susceptibility to the SARS-CoV-2. Figure S1. Result of sensitivity analysis – Baseline. Figure S2. Result of sensitivity analysis – The proportion of asymptomatic cases = 50%. Figure S3. Result of sensitivity analysis – Varying contact rates at schools = 0.8 times from the baseline. Figure S4. Result of sensitivity analysis – Varying contact rates at schools = 1.2 times from the baseline. Figure S5. Result of sensitivity analysis – Vaccine efficacy = lower bound of 95% confidence interval. Figure S6. Result of sensitivity analysis – Vaccine efficacy = upper bound of 95% confidence interval. Figure S7. Model validation in 3rd wave (pre-Delta). Figure S8. Model validation in 4th wave (Delta). Figure S9. Model validation in 5th wave (Omicron). Figure S10. MCMC trace plots and autocorrelation function (ACF) plots in 3rd wave (pre-Delta). Figure S11. MCMC trace plots and autocorrelation function (ACF) plots in 4th wave (Delta). Figure S12. MCMC trace plots and autocorrelation function (ACF) plots in 5th wave (Omicron). Table S1. Overview of Social Distancing System in South Korea. Table S2. School Attendance Ratio (%) during the 4th and 5th waves. Table S3. Vaccine coverage data in South Korea.

Acknowledgements

This study used the database of the KDCA and the NHIS for policy and academic research. The receipt number of this study is REQ202201596-002. The graphic work was supported by the Creative Media Service in National Cancer Center Korea.

Authors’ contributions

J.Y.C. and Y.K. conceived of the study, and H.J. performed the analysis. J.Y.C. and H.J. wrote the first draft of the manuscript. Y.K. reviewed and edited the manuscript. All authors interpreted the findings, contributed to writing the manuscript, and approved the final version for publication.

Funding

This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (No. 2020R1A2C1002301 and No. 2021R1F1A1064473). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Code and data to reproduce the analyses are available at https://github.com/Hwwichang/Age-varying-susceptibility-to-the-Omicron-variant-of-SARS-CoV-2.

Declarations

Ethics approval

All the data used in this study were deidentified and were regarded exempt from the institutional review board assessment of the National Cancer Center (NCC2022-0127).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 21 September 2022 Accepted: 8 November 2022

Published online: 23 November 2022

References

1. Belay ED, Godfrey-Cato S. SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge. Lancet Child Adolescent Health. 2022;6(S):280–1.

2. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Jachan R, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies - United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606–8.

3. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 34. UK Health Security Agency, 2022. [Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046853/technical-briefing-34-14-january-2022.pdf]. Accessed 31 May 2022.

4. World Health Organization. Coronavirus disease (COVID-19): vaccines. World Health Organization, 2022 [Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines?gclid=CjwKCAiwmIfhBRCARAIH-fc6poQl2UvS4wSe4oA0qZ8c3h9oFkY8fEEDF3kzKzO6WV-Mrh6I-bbW9ihvs5MuWbRxQl2jRqj_mJnkIJTUc3oATeEALw_wcB]. Accessed 30 May 2022.

5. Davies NG, Klepac P, Liu Y, Prem K, Ji M, Eggro RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–11.

6. Korea Disease Control and Prevention Agency. Infection disease surveillance system [Available from: http://www.cdc.go.kr/contents/es?mid=a2301110100]. Accessed 29 Aug 2022.

7. Korea Disease Control and Prevention Agency. COVID-19 vaccination [Available from: https://ncov.mohw.go.kr/]. Accessed 23 April 2022.

8. Korea Disease Control and Prevention Agency. Press Release: Korea COVID-19 Update [Available from: https://www.kdcda.go.kr/board/board.es/mid=a205010100008&bidx=0015]. Accessed 1 July 2022.

9. Chun JY, Jeong H, Kim Y. Age-varying susceptibility to the Delta variant (B.1.617.2) of SARS-CoV-2. JAMA Netw Open. 2022;5(3):e223064.

10. Ministry of health and welfare. Coronavirus disease-19, Republic of Korea [Available from: http://ncov.mohw.go.kr/]. Accessed 23 April 2022.

11. Korean Statistical Information Service. Population projection for Korea [Available from: https://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwd=MT_7ITTELEparmiTabld=M_01_01SelectStatSBoxDlv]. Accessed 10 Jan 2021.

12. Chun JY, Baek G, Kim Y. Transmission onset distribution of COVID-19. Int J Infect Dis. 2020;99:403–7.

13. Davies NG, Kucharski AJ, Eggro RM, Gimma A, Edmunds WJ. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health. 2020;5(7):e375–e85.

14. Dawood FS, Porucznik CA, Veguilla V, Stanford JB, Duque J, Rolfsz MA, et al. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. JAMA Pediatr. 2022;176(1):59–67.

15. Nakajo K, Nishura H. Transmissibility of asymptomatic COVID-19: data from Japanese clusters. Int J Infect Dis. 2021;102:58–65.

16. Johansson MA, Quandell JC, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e203505.

17. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94.

18. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27:2127–35. https://doi.org/10.1038/s41591-021-01548-7.

19. Polinski JM, Weckstein AR, Bateh M, Kabelac C, Kamath T, Harvey R, Jain S, Rassen JA, Khan N, Schneewess S. Effectiveness of the single-dose Ad26.COV2.S COVID vaccine. medRxiv. 2021. https://doi.org/10.1101/2021.09.10.21263385.

20. Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2 test negative case-control study. BMJ. 2021;375:e068848.

21. Andrews N, Stove J, Kirskebom F, Toffa S, Rickard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–46.

22. Vynnycky E, White R. An introduction to infectious disease modelling: OUP Oxford, 2010.

23. Prem K, Zandvoort KV, Klepac P, Eggro RM, Davies NG, Cook AR, et al. Projecting contact matrices in 177 geographical regions: an update and...
comparison with empirical data for the COVID-19 era. PLoS Comput Biol. 2021;17(7):e1009098.

24. Ministry of Education Republic of Korea. Remote learning and school opening information [Available from: https://www.moe.go.kr/boardCnts/listRenew.do?boardID=72754&cm=0313026s=moe]. Accessed 23 April 2022.

25. Google. COVID-19 community mobility reports [Available from: https://www.google.com/covid19/mobility/]. Accessed 23 April 2022.

26. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(11):422–8.

27. Marks KJ, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, et al. Hospitalizations of children and adolescents with laboratory-confirmed COVID-19 - COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):271–8.

28. Hui KPY, Ho JCY, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603(7902):715–20.

29. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, Sukhova K, Kafrou M, Bailey D, Barclay WS. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. 2022. https://doi.org/10.1101/2021.12.31.474653.

30. Choi YY, Kim YS, Lee SY, Sim J, Choe YJ, Han MS. Croup as a manifestation of SARS-CoV-2 Omicron variant infection in young children. J Korean Med Sci. 2022;37(20):e140.

31. Willett BJ, Grove J, MacLean OA, Willie C, Logan N, Lorenzo GD, et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. Nat Microbiol. 2022. https://doi.org/10.1038/s41564-022-01143-7.

32. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2020. https://doi.org/10.1136/archdischild-2020-320338.

33. Kim MC, Park JH, Choi SH, Chung JW. Rhinovirus incidence rates indicate we are tired of non-pharmacological interventions against coronavirus disease 2019. J Korean Med Sci. 2022;37(2):e15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.